Effect of Nebivolol on Endothelial Dysfunction in Coronary Artery Disease Patients -An Open Label Randomized Controlled Clinical Trial (NEDCAD)

Conclusion: Nebivolol (5 mg/day) has antioxidant benefit in patients with coronary artery disease and hypertension. The drug is well tolerated. The improvement in endothelial function could not be demonstrated in our study. Larger studies need to be carried.Keywords:Endothelial Function,Metoprolol,Nebivolol,Oxidative Stress.View:PDF (147.29 KB)Click here to download the PDF file.‹ Comparative Analysis of Clinical Profile of Patients Admitted with Idiopathic Dilated Cardiomyopathy in a Tertiary Care HospitalHomocysteine-Is there any role in Coronary Heart Disease? ›

Source: Journal of Cardiovascular Disease Research - July 3, 2017 Category: Cardiology Authors: yunus Source Type: research